Director/Chair Xiaodong Wang Files to Sell $47M in BeOne Medicines ADSs
ONC sits 37% above its 52-week low of $253.948.
Summary
Director/Chair Xiaodong Wang filed to sell $47.1 million in BeOne Medicines ADSs under a 10b5-1 plan, adding to a pattern of large insider sales at the company.
Key Events · Ownership and Investor Activity · ONC
-
Director/Chair Files $47M Sale
Xiaodong Wang, Director and Chair of BeOne Medicines, filed Form 144 to sell 131,370 ADSs worth approximately $47.1 million under a 10b5-1 plan adopted June 9, 2026.
-
Sale Includes Option Exercises and RSUs
The sale includes 124,110 shares from option exercises over the next three months and 7,260 RSUs vested between June 2022 and June 2026.
-
Adds to Insider Selling Pattern
This filing follows multiple large Form 144s from CEO John V. Oyler in recent months, including a $156.1 million filing on July 14, 2026, indicating a broader pattern of insider distribution.
-
10b5-1 Plan Adopted June 2026
The sale is pre-planned under a 10b5-1 trading plan adopted June 9, 2026, which provides an affirmative defense against insider trading allegations.
Analysis · ONC · Life Sciences
A Form 144 filed by Director and Chair Xiaodong Wang discloses plans to sell 131,370 ADSs worth approximately $47.1 million under a 10b5-1 plan adopted June 9, 2026. The sale includes 124,110 shares from option exercises over the next three months and 7,260 RSUs vested between June 2022 and June 2026. This adds to a pattern of insider selling at BeOne Medicines, where CEO John V. Oyler has filed multiple large Form 144s in recent months totaling over $200 million. While the sale is pre-planned under a 10b5-1 plan, the size and the fact that it comes from the board chair make it notable for investors.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONC was trading at $348.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.6B. The 52-week trading range was $253.95 to $385.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.